Key result
High polygenic risk is linked to ~42% greater odds of cognitive impairment and dementia.
Why the study?
African American adults have a high burden of late-life cognitive impairment and dementia but are underrepresented in genetic epidemiology studies investigating genetic risk and cardiometabolic disease contributions to dementia risk.
Are genetic risk and cardiometabolic diseases associated with cognitive impairment and dementia in African American adults?
Cohort (n=8,838)
Yes
Are genetic risk and cardiometabolic diseases associated with cognitive impairment and dementia in African American adults?
Odds Ratio: 1.42 (95% CI 1.12–1.78)
Genetic risk and cardiometabolic diseases independently contribute to dementia-related outcomes in African American adults, without significant interaction between the two.
Supports additive dementia risk from genetics and CMDs in AA adults; hypothesis-generating and should not yet alter practice.
BACKGROUND: African American (AA) adults have a high burden of late-life cognitive impairment (CI) and dementia but remain underrepresented in genetic epidemiology studies. Genetic risk and cardiometabolic diseases (CMDs) contribute to dementia risk. This study investigated whether genetic susceptibility and CMDs were associated with a composite CI outcome and whether CMDs modified these associations. METHODS: In AA participants within the REasons for Geographic and Racial Differences in Stroke (REGARDS) study, we assessed the association of a dementia polygenic risk score (PRS), APOE ε4 carrier status, and three prevalent CMDs: stroke, coronary artery disease (CAD), and type 2 diabetes (T2D) with a composite outcome of CI and dementia as a contributing cause of death (DCCD). We used logistic regression adjusted for age, sex, education, income, body mass index, smoking status, alcohol intake, physical activity, hypertension, low-density lipoprotein, and C-reactive protein. Interaction terms were included to assess whether CMDs modified the associations between genetic risk and the composite outcome. RESULTS: Of 8,838 participants, 516 (5.84 %) developed CI or had DCCD. In fully adjusted models, high polygenic risk (highest vs lowest PRS tertile) was associated with increased odds of the composite outcome [odds ratio (OR): 1.42; 95 % confidence interval (CI): 1.12-1.78], as was APOE ε4 carrier status (OR: 1.46; 95% CI: 1.21-1.78). Among CMDs, stroke (OR: 1.45; 95% CI: 1.04-2.02) and T2D (OR: 1.31; 95% CI: 1.06-1.61) were significantly associated with increased odds of the composite outcome. However, the association between genetic risk and the composite outcome did not significantly differ by CMD status. CONCLUSION: Genetic risk and CMDs independently contributed to dementia-related outcomes, indicating their relevance in understanding dementia risk among AA adults.
No takes yet. Share an insight, caveat, or question.
A 2025 study conducted a cohort in Cognitive impairment and dementia (n=8,838). High polygenic risk score, APOE ε4 carrier status, and cardiometabolic diseases vs. Lowest PRS tertile, APOE ε4 non-carriers, and absence of cardiometabolic diseases was evaluated on Composite outcome of cognitive impairment and dementia as a contributing cause of death (OR 1.42, 95% CI 1.12-1.78). High polygenic risk (OR 1.42; 95% CI 1.12-1.78), APOE ε4 carrier status, stroke, and type 2 diabetes were independently associated with increased odds of cognitive impairment and dementia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: